Epoetin Alfa: 4 agencies, 2004–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 22.1 years separate the first record, 30 Apr 2004 at AWMSG (Wales), from the most recent, 26 May 2026 at TLV (Sweden).
AWMSG (Wales) changed its position: restricted on 24 Sep 2010, not recommended by 13 Jul 2017.
No assessment is on file from PBAC (Australia), PHARMAC (New Zealand), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for epoetin alfa, 1 submission was never made — an outcome set by the company rather than the assessor.
Against its own class, epoetin alfa is an outlier: 86% of its decisive outcomes were positive, where molecules sharing ATC class B03X average 64%.
5 distinct indication wordings are recorded for epoetin alfa by the agencies that label one in English (AWMSG and SMC).
AWMSG (Wales) was first to assess epoetin alfa, on 30 Apr 2004; TLV (Sweden) did not open a file until 26 May 2026 — an unusually long tail of 22.1 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 11 years in total.
3 of the 4 agencies here assessed epoetin alfa more than once, HAS (France) most often at 10 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed epoetin alfa.
The full ledger for epoetin alfa reads 7 other, 5 recommended, 1 non-submission and 1 not recommended, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 8 Jan 2020 | Listing renewal (Transparency Committee) | SMR moderate | source |
| SMC (Scotland) | 11 Mar 2019 | Treatment of symptomatic anaemia (haemoglobin concentration of ≤10g/dL) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low se… | not recommended | source |
| HAS (France) | 7 Feb 2018 | Indication extension | SMR substantial · ASMR V | source |
| AWMSG (Wales) | 13 Jul 2017 | Treatment of symptomatic anaemia (haemoglobin concentration of ≤ 10 g/dL) in adults with low- or intermediate-1-risk pri… | not endorsed (non-submission) | source |
| HAS (France) | 20 Apr 2016 | Listing renewal (Transparency Committee) | SMR substantial | source |
11 further decisions for epoetin alfa, across 4 agencies, are not shown here. They include the most recent record on file, 26 May 2026 from TLV (Sweden); its outcome is in the subscriber dataset. They link to 6 further source documents.
Related molecules
- epoetin theta — divergent outcome (other vs recommended) on a shared indication
- luspatercept — same ATC class B03X — Antianemics
- roxadustat — same ATC class B03X — Antianemics
- darbepoetin alfa — same ATC class B03X — Antianemics
- epoetin zeta — same ATC class B03X — Antianemics
- insulin glargine — also decided by TLV in 2026Q2
Coverage: 16 decisions for epoetin alfa from 4 agencies, 2004 to 2026. Data to 7 Sep 2026. ATC class B03X — Antianemics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.